证券日报网讯 2月27日，阳光诺和发布2025年度业绩快报公告称，公司2025年实现营业总收入121781.33 万元，同比增长12.92%；实现归属于母公司所有者的净利润19608.33万元，同比增长10.53%。 （文章来源：证券日报） ...

公司的营业收入与利润达成了稳健增长态势，其核心驱动因素在于创新药管线的深入布局、授权合作的 价值实现，以及一体化服务模式的协同支持。 在创新药管线布局方面，公司聚焦于具备全球自主知识产权的创新药研发工作，构建了涵盖多肽、小核 酸、细胞和基因治疗等前沿领域的管线矩阵，其中包含20余种1类新药，涉及肿瘤、疼痛等重大疾病范 畴。依托"临床前+临床"一体化服务模式，结合完善的质量管理体系以及与300余家医院的临床合作网 络，公司高效推动研发项目的开展。其中，STC007、STC008等核心管线顺利步入关键临床阶段，不仅 借助研发服务获取稳定收入，还为长期价值的释放奠定了基础。同时，iCVETide等特色技术平台与AI 技术的融合运用，进一步提升了核心竞争力，助力研发管线快速推进。 授权合作与权益分成成为推动利润增长的关键动力。公司通过知识产权授权交易直接获取收益， STC007、STC008等管线的授权合作已贡献了相当可观的收入，形成了高毛利的收益来源，促使业务结 构持续优化。此外，"研发服务+管线培育+新质产业链"战略的实施，为业务增长提供了坚实的保障， 推动公司盈利水平稳步提升。 格隆汇2月27日丨阳光诺和(68 ...

Core Insights - The company reported a revenue of 1.218 billion yuan for the fiscal year 2025, representing a year-on-year growth of 12.92% [1] - The net profit attributable to the parent company was 196 million yuan, with a year-on-year increase of 10.53% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 184 million yuan, reflecting an 11.52% year-on-year growth [1] Group 1: Revenue and Profit Growth - The company's revenue and profit achieved steady growth, driven by the deep layout of its innovative drug pipeline, realization of value from licensing collaborations, and support from an integrated service model [1] - The innovative drug pipeline focuses on research and development of drugs with global independent intellectual property rights, covering cutting-edge fields such as peptides, small nucleic acids, cell, and gene therapy [1] - The company has established a pipeline matrix that includes over 20 first-class new drugs targeting major diseases such as cancer and pain [1] Group 2: Clinical and Operational Efficiency - The company efficiently promotes R&D projects through a "preclinical + clinical" integrated service model, supported by a comprehensive quality management system and a clinical cooperation network with over 300 hospitals [1] - Core pipelines like STC007 and STC008 have successfully entered critical clinical stages, providing stable income through R&D services and laying the foundation for long-term value release [1] - The integration of unique technology platforms like iCVETide with AI technology further enhances the company's core competitiveness and accelerates the advancement of its R&D pipeline [1] Group 3: Profit Growth Drivers - Licensing collaborations and revenue sharing have become key drivers of profit growth, with significant income generated from the licensing of pipelines such as STC007 and STC008, forming a high-margin revenue source [2] - The implementation of the "R&D services + pipeline cultivation + new quality industrial chain" strategy provides solid support for business growth, steadily improving the company's profitability [2]

2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载北京阳光诺和药物研究股份有限公司（以下简称"公司"）2025 年度主要财务数据和指标为初步核算数据，未经会计师事务所审计，具体数据以 公司 2025 年年度报告为准，提请投资者注意投资风险。 证券代码：688621 证券简称：阳光诺和 公告编号：2026-014 北京阳光诺和药物研究股份有限公司 一、2025 年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（%） | | --- | --- | --- | --- | | 营业总收入 | 121,781.33 | 107,847.38 | 12.92 | | 营业利润 | 20,419.68 | 17,768.90 | 14.92 | | 利润总额 | 20,107.94 | 17,598.73 | 14.26 | | 归属于母公司所有者 | 19,608.33 | 17,740.95 | 10.53 | | 的净利润 | | | | | 归属于 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Core Insights - The company has made significant advancements in research and development, particularly with its nucleic acid drug platform, which has received clinical trial acceptance for ABA001, aimed at treating hypertension, expected to enter Phase I trials in Q2 2026 [1] Product Development Progress - STC007, a non-addictive postoperative analgesic, is currently in Phase III clinical trials and is expected to submit a new drug application within 2025, potentially becoming the company's first approved innovative drug [2] - STC008, a targeted cancer drug, has entered a critical clinical stage, with the company accelerating its development through an integrated service network [2] Performance and Operating Conditions - The company has released a revenue forecast for 2025, estimating revenue between 1.192 billion and 1.371 billion yuan, representing a year-on-year growth of 10.57% to 27.15%. The net profit attributable to shareholders is projected to be between 191 million and 229 million yuan, with a year-on-year increase of 7.69% to 29.23%. The formal annual report is expected to be disclosed around April 2026 [3] Strategic Advancement - On January 27, 2026, the company announced the termination of the transaction to acquire 100% equity of Langyan Life through the issuance of shares and convertible bonds, indicating a stronger focus on innovative drug development and a "R&D services + pipeline cultivation" strategy [4] Future Development - The company plans to accelerate the layout of its nucleic acid platform and AI peptide platform for multiple indications in 2026, targeting areas such as fat reduction, muscle gain, high blood sugar, and Alzheimer's disease, with the AI peptide platform expected to add 2-3 new drugs in clinical stages [5]

Core Insights - The small nucleic acid sector is experiencing a significant commercialization phase, driven by technological breakthroughs and successful clinical data releases in the weight loss domain [1][3][6] - Major transactions, including a billion-level acquisition by China Biologic and the Hong Kong listing of Rebio, indicate that capital exit channels are now open [1][5][6] Group 1: Clinical Data Releases - Arrowhead Pharmaceuticals announced clinical data for two siRNA obesity candidates, ARO-INHBE and ARO-ALK7, showing improvements in visceral fat and total fat in obese patients with type 2 diabetes, leading to a 10.9% stock price increase [3] - Wave Life Sciences reported that its siRNA drug WVE-007 achieved a 4.0% weight reduction and a 0.9% muscle gain in a Phase I trial, resulting in a 147.3% stock price surge [4] - The clinical data from these small nucleic acid drugs suggest potential for use either alone or in combination with GLP-1 drugs to reduce fat while preserving muscle [4][7] Group 2: Business Development Transactions - In early 2026, Anlong Bio secured an international strategic cooperation agreement in the small nucleic acid drug field worth over $100 million, marking a significant breakthrough in international business development [5] - China Biologic announced a 1.2 billion RMB acquisition of Hejiya Bio, enhancing its small nucleic acid portfolio and leveraging Hejiya's unique long-acting delivery platform [5][6] - Saintin Bio has engaged in multiple business development deals, including a strategic collaboration with Genentech worth up to $15 billion for RNAi drug development [17] Group 3: Market Trends and Future Outlook - The small nucleic acid sector is increasingly recognized as a core area for innovative drug development, with expectations for more significant events in the future [2][6] - The weight loss market is identified as a potential area for major transactions, driven by the large market size and the growing recognition of clinical efficacy for small nucleic acid drugs [7][19] - Major pharmaceutical companies are actively exploring collaborations in the small nucleic acid space, particularly in conjunction with GLP-1 drugs to enhance therapeutic outcomes [18][20]

Group 1 - The core point of the announcement is the change in the signing project partner for the year 2025 from Peng Xinming to Cheng Luoming [1] - The signing registered accountant has been changed from Cheng Luoming to Mai Jiahui, and this change has been confirmed by Zheng Dan Zhi Yuan (Shenzhen) Accounting Firm [1] - The transition of responsibilities has been completed and will not affect the annual audit [1]

证券代码：688621 证券简称：阳光诺和 公告编号：2026-013 北京阳光诺和药物研究股份有限公司 关于公司诉讼事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司收到湖南省衡阳市中级人民法院民事判决书（2025）湘 04 知民初 34 号的一审判决结果，具体内容详见公司于 2026 年 1 月 28 日刊登在上海证券交易 所网站的（www.sse.com.cn）的《北京阳光诺和药物研究股份有限公司关于公司 诉讼事项的进展公告》（公告编号：2026-007）。 作为上诉人，近期公司提交《民事上诉状》，上诉状主要内容如下： 涉案金额：（2025）湘 04 知民初 34 号一审判决金额为湖南恒生制药股 份有限公司（以下简称"恒生制药"）向北京阳光诺和药物研究股份有限公司（以 下简称"阳光诺和"或"公司"）支付拖欠研发费用合计 12 万元及相应逾期支 付违约金，阳光诺和向恒生制药支付违约金 32 万元； 是否会对上市公司损益产生负面影响：公司根据审慎性原则按照会计准 则已对恒生制药应收账款和 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2026-012 北京阳光诺和药物研究股份有限公司 关于变更签字项目合伙人及签字注册会计师的公告 二、本次变更人员的基本信息 签字项目合伙人：程罗铭先生，2017 年 8 月成为注册会计师，2009 年 10 月 开始从事上市公司和挂牌公司审计，2024 年 12 月开始在政旦志远执业，2022 年 开始为公司提供审计服务，近三年签署上市公司和挂牌公司审计报告数量超过 1 近日，公司收到政旦志远出具的《关于变更北京阳光诺和药物研究股份有限 公司 2025 年度签字项目合伙人及签字注册会计师的函》，现将有关情况公告如 下： 一、本次签字项目合伙人、签字注册会计师变更的基本情况 10 家。 政旦志远作为公司聘任的 2025 年度审计机构、内部控制审计机构，原委派 彭新明先生担任公司 2025 年度签字项目合伙人，程罗铭先生担任公司 2025 年度 签字注册会计师。鉴于原签字项目合伙人及签字注册会计师工作调整，现将公司 签字项目合伙人变更为程罗铭先生，签字注册会计师变更为麦家辉先生。 签字注册会计师：麦家辉先生，2018 年 2 月成为注册会计师，2018 年 ...